LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has entered into an agreement to acquire the ...

SAN DIEGO--(BUSINESS WIRE)--ImThera Medical Inc. today announced European CE Mark (Conformité Européenne) approval of its aura6000™ system for the treatment of obstructive sleep apnea (OSA). The ...

THN3 Study Will Expand the Clinical Evidence for this Novel Neurostimulation Therapy for Moderate to Severe Obstructive Sleep Apnea "This is a substantial milestone in the development of this ...

Some 800,000 people in the U.S. are diagnosed each year with obstructive sleep apnea, in which the tongue relaxes during the onset of sleep to the point of physically blocking much of the upper airway ...

Medical device company ImThera Medical announced that the first two patients in its international obstructive sleep apnea clinical study have been implanted with the company's aura6000 system. The ...

LivaNova PLC, a health care company that has its North American headquarters in Houston, is pursuing its largest acquisition since its multibillion-dollar merger in 2015. Earlier this month, LivaNova ...

ImThera Medical Inc. put to bed more than $1 million of a possible $2.2 million funding round that will go toward completing clinical trials of an implantable neurostimulation device for sleep apnea.

Livanova plc agreed to acquire Imthera Medical Inc. by purchasing remaining shares in the firm, valued at up to $225 million with an initial payment of $78 million and the remainder on a ...

If you're someone who's never had to deal with sleep apnea, as I am, it may come as a surprise to learn that the most effective--and frequently prescribed--device to treat the disorder, CPAP, is an ...

Obstructive sleep apnea, OSA, is much more than a nuisance and a disturber of sleep. It is the most common type of sleep disordered breathing, affecting 38 million patients in the United States – but ...

LivaNova has been an investor in ImThera since 2011 and has agreed to pay up to approximately $225 million to acquire the remaining outstanding interests of ImThera. Up-front costs are approximately ...

* LIVANOVA PLC SAYS ENTERED INTO AN AGREEMENT TO ACQUIRE REMAINING OUTSTANDING INTERESTS IN IMTHERA MEDICAL, INC. * LIVANOVA PLC SAYS HAS AGREED TO PAY UP TO APPROXIMATELY $225 MILLION TO ACQUIRE ...